Alnylam Pharmaceuticals
ALNY
#581
Rank
ยฃ27.34 B
Marketcap
ยฃ212.00
Share price
2.75%
Change (1 day)
60.01%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : ยฃ1.00 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ1.00 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B47.66%
2021-12-31ยฃ0.73 B93.28%
2020-12-31ยฃ0.38 B65.03%
2019-12-31ยฃ0.23 B880.35%
2018-12-31ยฃ23.63 M6.47%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.4 M-27.07%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.33%
2004-12-31ยฃ3.75 M260.93%
2003-12-31ยฃ1.03 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
ยฃ91.4 M-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.09 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.06 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.20 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.52 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.43 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ19.70 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ14.64 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel